



Extracellular GAPDH Promotes Alzheimer Disease Progression by Enhancing Amyloid- β Aggregation and Cytotoxicity

Vladimir F. Lazarev^{1,2}, Magda Tsolaki³, Elena R. Mikhaylova¹, Konstantin A. Benken⁴, Maxim A. Shevtsov^{1,5}, Alina D. Nikotina¹, Mirna Lechpammer⁶, Vladimir A. Mitkevich², Alexander A. Makarov², Alexey A. Moskalev^{2,7}, Sergey A. Kozin², Boris A. Margulis^{1*}, Irina V. Guzhova^{1*}, Evgeny Nudler^{6,8*}

SUPPLEMENTARY DATA




Supplementary Figure 1. GAPDH and Aβ42 form SDS insoluble complex in the presence of tTG.



Supplementary Figure 2. An arbitrary cytosolic protein (LDH) released from dying cells does not form insoluble aggregates with Aβ.

SUPPLEMENTARY DATA



Supplementary Figure 3. Variation of GAPDH content in hippocampus leads to changes in death and apoptosis levels in rat and mouse models of AD. (A) Lesions volume of rats two months after injection of A β 42 together with lentiviral pLOC-GAPDH or A β 42 together with lentiviral shGAPDH RNA, presented on Fig. 4C measured with the aid of TotalLab software (n = 3 for each group); *, p < 0.05; **, p < 0.01. (B) The prevalence of apoptotic cells in rat hippocampi was calculated as the ratio of TUNEL-positive cells to DAPI-stained cells on histological slices using TotalLab software (n = 3 for each group), see Fig. 4D. (C) The prevalence of apoptotic cells in mouse hippocampi presented on Fig. 4E was calculated as in (B) (n = 3 for each group); *, p < 0.05.

Supplementary Table 1. Cohort of MCI and AD patients used for GAPDH detection in CSF.

| # | Stage of Disease | Number of patients in group | Average age | MMSE, range |
|---|------------------|-----------------------------|----------------|-------------|
| 1 | MCI | n=22; 12 males, 10 females | 69,4 \pm 2,5 | 26-30 |
| 2 | Mild AD | n=41; 22 males, 19 females | 75,5 \pm 1,1 | 21-25 |
| 3 | Moderate AD | n=49; 26 males, 23 females | 75,6 \pm 0,9 | 12-20 |
| 4 | Severe AD | n=51; 31 males; 20 females | 74,8 \pm 3,5 | 0-11 |

Supplementary Table 2. Cohort of MCI and AD disease patients used for detecting A β -GAPDH aggregates in CSF.

| # | Stage of Disease | Number of patients in group | Average age | MMSE, range |
|---|------------------|-----------------------------|----------------|-------------|
| 1 | MCI | n=6; 4 males, 2 females | 71,5 \pm 2,5 | 26-28 |
| 2 | Mild AD | n=8; 6 males, 2 females | 76 \pm 2,2 | 21-25 |
| 3 | Moderate AD | n=7; 3 males, 4 females | 78,3 \pm 2,4 | 12-20 |
| 4 | Severe AD | n=6; 3males; 3 females | 74,8 \pm 3,5 | 0-11 |